Ventripoint’s VMS+ 4.0 Files for NMPA Approval, Showcases at AEPC with Multiple Partnerships
Ventripoint Diagnostics submitted its VMS+ 4.0 cardiac AI imaging system for approval via China’s NMPA green channel on April 28, targeting 330 million cardiovascular disease patients. It also exhibited at AEPC in Padua and secured U.S. and Indigenous partnerships plus an Edison Award, stacking regulatory and commercial validations.
1. NMPA Submission and Market Opportunity
On April 28, Ventripoint’s partner Lishman Global submitted the VMS+ 4.0 system to China’s National Medical Products Administration via the expedited green channel. This filing opens access to an estimated 330 million cardiovascular disease patients in China, leveraging existing ultrasound infrastructure for MRI-equivalent volumetric measurements.
2. AEPC Exhibition in Padua
From May 12–16, Ventripoint showcased VMS+ 4.0 at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology in Padua. The booth highlighted the system’s fast, point-of-care volumetric analysis for congenital heart disease, aligning with ESC guidelines for lifelong ventricular function monitoring.
3. Broader Validation and Partnerships
Since early 2026, Ventripoint has amassed an Edison Award, a commercial agreement with LG Consulting Solutions for Northern California hospitals, and an AI 3D heart-mapping deployment in Nisg̱a’a Indigenous communities. These milestones demonstrate its strategy of stacking regulatory clearances, clinical evidence and commercial deals to convert pilot data into recurring revenue.